Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents

Pediatric Nephrology

Volumn 25, Issue 5, 2010, Pages 801-811

  Herder, Siegtraut Dorothea ^a   Weber, Ernst ^b   Winkemann, Almuth ^c   Herder, Christoph ^d   Morck, Hartmut ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c General Practitioner in Private Practice   (Germany)

^d Pediatrician in Private Practice   (Germany)

Author keywords

Adolescents; Angiotensin receptor antagonists; Children; Hypertension; Nephropathy; Pediatric

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ADD ON THERAPY; ADOLESCENT; ADOLESCENT DISEASE; ALBUMINURIA; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; BLURRED VISION; CHILD; CHILD SAFETY; CHILDHOOD DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; COUGHING; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBRYOTOXICITY; ERYTHEMA; FATIGUE; FOLLOW UP; FRACTURE; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; HYDRAMNIOS; HYPERTENSION; KIDNEY DISEASE; LEUKOPENIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; REVIEW; RHINITIS; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; INFANT; KIDNEY DISEASES; PATIENT SELECTION; PROTEINURIA; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77951255686     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-009-1346-z     Document Type: Review

References (65)

1. L Cuzzolin A Atzei V Fanos 2006 Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety Expert Opin Drug Saf 5 703 718 10.1517/14740338.5.5.703 16907660 (Pubitemid 44322888)
2. M Dell'Aera AR Gasbarro M Padovano N Laforgia D Capodiferro B Solarino R Quaranta AS Dell'Erba 2007 Unlicensed and off-label use of medicines at a neonatology clinic in Italy Pharm World Sci 29 361 367 10.1007/s11096-006-9081-z 17351821 (Pubitemid 47196657)
3. M Grimm C Gebauer T Kapellen O Brosteanu W Kiess 2007 Wie sicher sind pädiatrische Arzneimittelverordnungen? Kinder- und Jugendmedizin 6 345 350
4. DB Hawcutt RL Smyth 2008 Drug development for children: how is pharma tackling an unmet need? IDrugs 11 502 507 18600597
5. K Hoppu 2008 Paediatric clinical pharmacology: at the beginning of a new era Eur J Clin Pharmacol 64 201 205 10.1007/s00228-007-0390-5 17972069
6. F Marchetti J Bua A Ventura LD Notarangelo S Di Maio G Migliore M Bonati 2007 The awareness among paediatricians of off-label prescribing in children: a survey of Italian hospitals Eur J Clin Pharmacol 63 81 85 10.1007/s00228-006- 0223-y 17124577 (Pubitemid 46025477)
7. A Neubert IC Wong A Bonifazi M Catapano M Felisi P Baiardi C Giaquinto CA Knibbe MC Sturkenboom MA Ghaleb A Ceci 2008 Defining off-label and unlicensed use of medicines for children: results of a Delphi survey Pharmacol Res 58 316 322 10.1016/j.phrs.2008.09.007 18852048
8. DB Santos A Clavenna M Bonati HL Coelho 2008 Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil Eur J Clin Pharmacol 64 1111 1118 10.1007/s00228-008-0543-1 18685837
9. GK Aulakh RK Sodhi M Singh 2007 An update on non-peptide angiotensin receptor antagonists and related RAAS modulators Life Sci 81 615 639 10.1016/j.lfs.2007.06.007 1:CAS:528:DC%2BD2sXpsFWqtbc%3D 17692338 (Pubitemid 47271905)
10. G Cortina S Wiesmayr T Jungraithmayr L Zimmerhackl 2007 Arterielle Hypertonie im Kindes- und Jugendalter Pädiatr Praxis 70 29 40
11. Abt K (1988) Statistics and topography in quantitative EEG studies. Elsevier, Paris
12. K Abt 1987 Descriptive data analysis: a concept between confirmatory and exploratory data analysis Methods Inf Med 26 77 88 1:STN:280: DyaL2s3ivVeitQ%3D%3D 3587055 (Pubitemid 17094791)
13. S Shahinfar F Cano BA Soffer T Ahmed EP Santoro Z Zhang G Gleim K Miller B Vogt J Blumer I Briazgounov 2005 A double-blind, dose-response study of losartan in hypertensive children Am J Hypertens 18 183 190 10.1016/j.amjhyper. 2004.09.009 1:CAS:528:DC%2BD2MXislCkurc%3D 15752945 (Pubitemid 40332547)
14. Higgins J, Green S (2008) Cochrane handbook for systematic reviews of interventions, Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. In: Higgins J, Green S (eds) Available from www.cochrane- handbook.org
15. CT White CF Macpherson RM Hurley DG Matsell 2003 Antiproteinuric effects of enalapril and losartan: a pilot study Pediatr Nephrol 18 1038 1043 10.1007/s00467-003-1190-5 12920631 (Pubitemid 37236219)
16. FDA (2004) Clinical Pharmacology Reviews of Irbesartan. Available at http://wwwfdagov/cder/foi/esum/2005/20757s034-Avapro-Clinical-BPCApdf
17. JT Flynn KE Meyers JP Neto R de Paula Meneses A Zurowska A Bagga L Mattheyse V Shi J Gupte S Solar-Yohay G Han 2008 Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years Hypertension 52 222 228 10.1161/HYPERTENSIONAHA.108.111054 1:CAS:528:DC%2BD1cXosFyqu7g%3D 18591457
18. H Trachtman JW Hainer J Sugg R Teng JM Sorof J Radcliffe Candesartan in Children with Hypertension Investigators 2008 Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years J Clin Hypertens (Greenwich) 10 743 750 10.1111/j.1751-7176.2008.00022.x 1:CAS:528:DC%2BD1cXhsVOgu7bO
19. AC Gartenmann E Fossali RO von Vigier GD Simonetti J Schmidtko A Edefonti MG Bianchetti 2003 Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood Kidney Int 64 1450 1454 10.1046/j.1523-1755.2003.00238.x 1:CAS:528:DC%2BD3sXotFyru78%3D 12969165 (Pubitemid 37153812)
20. M Salcedo-Alejos F Banda-Espinoza M Rodriguez-Moran F Guerrero-Romero 2005 Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial Nephrol Dial Transplant 20 2120 2125 10.1093/ndt/gfh728 1:CAS:528: DC%2BD2MXhtVWnt7fL 16091379 (Pubitemid 41510086)
21. AM Franks CE O'Brien CD Stowe TG Wells SF Gardner 2008 Candesartan cilexetil effectively reduces blood pressure in hypertensive children Ann Pharmacother 42 1388 1395 10.1345/aph.1L212 1:CAS:528:DC%2BD1cXht1enur3M 18664605
22. Y Yang K Ohta M Shimizu A Nakai Y Kasahara A Yachie S Koizumi 2005 Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy Clin Nephrol 64 35 40 1:STN:280:DC%2BD2MzovFSksA%3D%3D 16047643 (Pubitemid 40975063)
23. D Ellis A Vats ML Moritz S Reitz MJ Grosso JE Janosky 2003 Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria J Pediatr 143 89 97 10.1016/S0022-3476(03)00279-8 1:CAS:528:DC%2BD3sXmt1egsLk%3D 12915830 (Pubitemid 36928574)
24. L Butani 2005 Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria Pediatr Nephrol 20 1651 1654 10.1007/s00467-005-2031-5 16133038 (Pubitemid 41554483)
25. RO von Vigier PM Zberg O Teuffel MG Bianchetti 2000 Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease Eur J Pediatr 159 590 593 10.1007/s004310000495 (Pubitemid 30469446)
26. LM Franscini RO Von Vigier R Pfister C Casaulta-Aebischer E Fossali MG Bianchetti 2002 Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases Am J Hypertens 15 1057 1063 10.1016/S0895-7061(02)03083-2 1:CAS:528:DC%2BD3sXisFCl 12460701 (Pubitemid 35397539)
27. D Ellis ML Moritz A Vats JE Janosky 2004 Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders Am J Hypertens 17 928 935 1:CAS:528:DC%2BD2cXos12ju74%3D 15485756 (Pubitemid 39361665)
28. GD Simonetti RO von Vigier M Konrad M Rizzi E Fossali MG Bianchetti 2006 Candesartan cilexetil in children with hypertension or proteinuria: preliminary data Pediatr Nephrol 21 1480 1482 10.1007/s00467-006-0162-y 16802178 (Pubitemid 44203462)
29. M Litwin R Grenda J Sladowska J Antoniewicz 2006 Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors Pediatr Nephrol 21 1716 1722 10.1007/s00467-006-0223-2 16909244 (Pubitemid 44390838)
30. A Sakarcan F Tenney JT Wilson JJ Stewart KG Adcock TG Wells NN Vachharajani OW Hadjilambris P Slugg NF Ford MR Marino 2001 The pharmacokinetics of irbesartan in hypertensive children and adolescents J Clin Pharmacol 41 742 749 10.1177/00912700122010645 1:CAS:528:DC%2BD3MXlsFShsbk%3D 11452706 (Pubitemid 32612437)
31. M Bald M Holder M Zieger M Vochem HE Leichter 2005 Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy Pediatr Nephrol 20 1666 1668 10.1007/s00467-005-1938-1 (Pubitemid 41554488)
32. JK Bass RG Faix 2006 Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant Am J Perinatol 23 313 317 10.1055/s-2006-947162 16799914
33. MA Bos-Thompson D Hillaire-Buys F Muller H Dechaud E Mazurier P Boulot D Morin 2005 Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth Ann Pharmacother 39 157 161 15590878 (Pubitemid 40052394)
34. RM Cox JM Anderson P Cox 2003 Defective embryogenesis with angiotensin II receptor antagonists in pregnancy BJOG 110 1038 10.1111/j.1471-0528.2003.02139. x 1:STN:280:DC%2BD3srhtl2lug%3D%3D 14592593 (Pubitemid 37338497)
35. GG Briggs MP Nageotte 2001 Fatal fetal outcome with the combined use of valsartan and atenolol Ann Pharmacother 35 859 861 10.1345/aph.1A013 1:STN:280:DC%2BD38%2FislCrsA%3D%3D 11485133
36. C Pietrement L Malot B Santerne B Roussel J Motte P Morville 2003 Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist J Perinatol 23 254 255 10.1038/sj.jp.7210871 1:CAS:528:DC%2BD3sXjsVWrtb8%3D 12732865 (Pubitemid 36656529)
37. GD Simonetti T Baumann JM Pachlopnik RO von Vigier MG Bianchetti 2006 Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan Pediatr Nephrol 21 1329 1330 10.1007/s00467-006-0162-y 16807764 (Pubitemid 44203462)
38. H Saji M Yamanaka A Hagiwara R Ijiri 2001 Losartan and fetal toxic effects Lancet 357 363 10.1016/S0140-6736(00)03648-5 1:STN:280: DC%2BD3M7is1yitA%3D%3D 11211003 (Pubitemid 32128547)
39. S Fujinaga K Kaneko Y Ohtomo Y Yamashiro 2006 Acute renal failure induced by an angiotensin II receptor antagonist in a 14-year-old boy with reflux nephropathy Pediatr Nephrol 21 601 602 10.1007/s00467-006-0038-1 16534606
40. CD Hanevold 2006 Acute renal failure during lisinopril and losartan therapy for proteinuria Pharmacotherapy 26 1348 1351 10.1592/phco.26.9.1348 16945058 (Pubitemid 44306895)
41. GD Simonetti MG Bianchetti M Konrad RO von Vigier 2007 Severe anemia caused by the angiotensin receptor blocker irbesartan after renal transplantation Pediatr Nephrol 22 756 757 10.1007/s00467-006-0400-3 17216246 (Pubitemid 46691537)
42. P Donati-Genet MG Bianchetti 1996 Modulators of the renin-angiotensin- aldosterone system and cough in childhood Pediatr Nephrol 10 545 546 1:STN:280:DyaK2s%2FhvVKnuw%3D%3D 8865265 (Pubitemid 26261623)
43. NN Vachharajani WC Shyu RA Smith DS Greene 1998 The effects of age and gender on the pharmacokinetics of irbesartan Br J Clin Pharmacol 46 611 613 10.1046/j.1365-2125.1998.00837.x 1:STN:280:DyaK1M%2FnslSlug%3D%3D 9862252 (Pubitemid 28522127)
44. R Bhattacharjee G Filler 2002 Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy Pediatr Nephrol 17 302 304 10.1007/s00467-002-0829-y 11956889 (Pubitemid 36097302)
45. S Alwan JE Polifka JM Friedman 2005 Angiotensin II receptor antagonist treatment during pregnancy Birth Defects Res A Clin Mol Teratol 73 123 130 10.1002/bdra.20102 1:CAS:528:DC%2BD2MXitVWlur8%3D 15669052 (Pubitemid 40289535)
46. J Martinovic A Benachi N Laurent F Daikha-Dahmane MC Gubler 2001 Fetal toxic effects and angiotensin-II-receptor antagonists Lancet 358 241 242 10.1016/S0140-6736(01)05426-5 1:STN:280:DC%2BD3MvjtlSrsg%3D%3D 11480433 (Pubitemid 32718555)
47. GD Simonetti M Rizzi R Donadini MG Bianchetti 2007 Effects of antihypertensive drugs on blood pressure and proteinuria in childhood J Hypertens 25 2370 2376 10.1097/HJH.0b013e3282efeb7e 1:CAS:528:DC%2BD2sXht1Gqu7fN 17984655 (Pubitemid 350060374)
48. LG Feld H Corey 2007 Hypertension in childhood Pediatr Rev 28 283 298 10.1542/pir.28-8-283 17670953 (Pubitemid 47282264)
49. JM Bergstein 1999 A practical approach to proteinuria Pediatr Nephrol 13 697 700 10.1007/s004670050684 1:STN:280:DyaK1MvjtFGqtg%3D%3D 10502130 (Pubitemid 29438453)
50. Kidney Disease Outcomes Quality Initiative (K/DOQI) 2004 K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 S1 290
51. N Yoshikawa R Tanaka K Iijima 2001 Pathophysiology and treatment of IgA nephropathy in children Pediatr Nephrol 16 446 457 10.1007/s004670100582 1:STN:280:DC%2BD3Mzkt1aqtA%3D%3D 11405121 (Pubitemid 32447711)
52. J Lv H Zhang Y Zhou G Li W Zou H Wang 2008 Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China Nephrology (Carlton) 13 242 246 10.1111/j.1440-1797.2007.00898.x (Pubitemid 351341460)
53. F Assadi 2007 Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension Pediatr Cardiol 28 27 33 10.1007/s00246-006-1390-4 17308944 (Pubitemid 46311144)
54. G Wolf J Misselwitz 2009 Proteinurie und progression von Nierenerkrankungen Päd 15 80 84
55. JT Flynn 2003 Ethics of placebo use in pediatric clinical trials: the case of antihypertensive drug studies Hypertension 42 865 869 10.1161/01.HYP.0000095616.91352.2E 1:CAS:528:DC%2BD3sXosFCmtL8%3D 14504262 (Pubitemid 37413721)
56. DK Benjamin Jr PB Smith P Jadhav JV Gobburu MD Murphy V Hasselblad C Baker-Smith RM Califf JS Li 2008 Pediatric antihypertensive trial failures: analysis of end points and dose range Hypertension 51 834 840 10.1161/HYPERTENSIONAHA.107.108886 1:CAS:528:DC%2BD1cXjtV2gtr4%3D 18332283 (Pubitemid 351654692)
57. RJ Smith J Alexander PN Barlow M Botto TL Cassavant HT Cook SR de Cordoba GS Hageman TS Jokiranta WJ Kimberling JD Lambris LD Lanning V Levidiotis C Licht HU Lutz S Meri MC Pickering RJ Quigg AL Rops DJ Salant S Sethi JM Thurman HF Tully SP Tully J van der Vlag PD Walker R Wurzner PF Zipfel 2007 New approaches to the treatment of dense deposit disease J Am Soc Nephrol 18 2447 2456 10.1681/ASN.2007030356 1:CAS:528:DC%2BD2sXhtV2mur3L 17675665 (Pubitemid 47378860)
58. GB Pylypchuk 1998 ACE inhibitor versus angiotensin II blocker-induced cough and angioedema Ann Pharmacother 32 1060 1066 10.1345/aph.17388 1:CAS:528:DyaK1cXmvFyrsrk%3D 9793599 (Pubitemid 28498467)
59. KS Lo 2002 Angioedema associated with candesartan Pharmacotherapy 22 1176 1179 10.1592/phco.22.13.1176.33516 12222554
60. BK Irons A Kumar 2003 Valsartan-induced angioedema Ann Pharmacother 37 1024 1027 10.1345/aph.1C520 12841812 (Pubitemid 36875233)
61. D Ellis 2002 Combined use of enalapril and losartan to reduce proteinuria: a question of safety Am J Kidney Dis 39 209 211 11774126 (Pubitemid 34062519)
62. KF Hilgers J Dotsch W Rascher JF Mann 2004 Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 19 956 961 10.1007/s00467-004-1554-5 15278690 (Pubitemid 39242774)
63. CM Meier GD Simonetti S Ghiglia E Fossali P Salice C Limoni MG Bianchetti 2007 Palatability of angiotensin II antagonists among nephropathic children Br J Clin Pharmacol 63 628 631 10.1111/j.1365-2125.2006.02814.x 1:CAS:528:DC%2BD2sXntFOrsLo%3D 17302913 (Pubitemid 46632576)
64. C Pozzi L Del Vecchio D Casartelli P Pozzoni S Andrulli A Amore L Peruzzi R Coppo F Locatelli 2006 ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study J Nephrol 19 508 514 1:CAS:528:DC%2BD2sXhtVOgs7s%3D 17048209 (Pubitemid 44823207)
65. RV Lacro HC Dietz LM Wruck TJ Bradley SD Colan RB Devereux GL Klein JS Li LL Minich SM Paridon GD Pearson BF Printz RE Pyeritz E Radojewski MJ Roman JP Saul MP Stylianou L Mahony 2007 Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome Am Heart J 154 624 631 10.1016/j.ahj.2007.06.024 1:CAS:528:DC%2BD2sXhtVOit7rK 17892982 (Pubitemid 47429596)